LABELS · 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

Docetaxel

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-08-01
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with Docetaxel Injection is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive Docetaxel Injection as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions ( 5.1 )] . Avoid the use of Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 x ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection [see Warnings and Precautions ( 5.2 )] . Do not administer Docetaxel Injection to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions ( 5.3 )] . Do not administer Docetaxel Injection to patients who have a history of severe hypersensitivity reactions to Docetaxel Injection or to other drugs formulated with polysorbate 80 [see Contraindications ( 4 )] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel infusion and administration of appropriate therapy [see Warnings and Precautions ( 5.5 )] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions ( 5.6 )] . WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving Docetaxel Injection at 100 mg/m 2 ( 5.1 ) Avoid use of Docetaxel Injection if bilirubin > ULN, or if AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) Do not administer Docetaxel Injection to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of Docetaxel Injection and administration of appropriate therapy ( 5.5 ) Contraindicated if history of severe hypersensitivity reactions to Docetaxel Injection or to drugs formulated with polysorbate 80 ( 4 ) Severe fluid retention may occur despite dexamethasone ( 5.6 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Full extracted label fields

application numbers

NDA203551

boxed warning exact

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with Docetaxel Injection is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive Docetaxel Injection as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions ( 5.1 )] . Avoid the use of Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 x ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection [see Warnings and Precautions ( 5.2 )] . Do not administer Docetaxel Injection to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions ( 5.3 )] . Do not administer Docetaxel Injection to patients who have a history of severe hypersensitivity reactions to Docetaxel Injection or to other drugs formulated with polysorbate 80 [see Contraindications ( 4 )] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel infusion and administration of appropriate therapy [see Warnings and Precautions ( 5.5 )] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions ( 5.6 )] . WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving Docetaxel Injection at 100 mg/m 2 ( 5.1 ) Avoid use of Docetaxel Injection if bilirubin > ULN, or if AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) Do not administer Docetaxel Injection to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of Docetaxel Injection and administration of appropriate therapy ( 5.5 ) Contraindicated if history of severe hypersensitivity reactions to Docetaxel Injection or to drugs formulated with polysorbate 80 ( 4 ) Severe fluid retention may occur despite dexamethasone ( 5.6 )

brand names

Docetaxel

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f

generic names

DOCETAXEL

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

indications and usage exact

1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

indications and usage tables exact

is original packager

true

manufacturer names

Actavis Pharma, Inc.

matched search terms

cancer
carcinoma

package ndcs

45963-734-54
45963-765-52

product ndcs

45963-734
45963-765

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1860480
1860485

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA203551

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1100
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combinat
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 0

current approval status

not_reconciled

duplicate text group

dup-b274703c4939b13bba76

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-0cd9614ef16bd11e3df3

label id

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

positive predicate support span

end: 80
end exclusive: true
exact text: is a microtubule inhibitor indicated
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 44

qualifier mentions

context exact
r: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant trea
kind
biomarker
polarity
not_inferred
span
end
183
end exclusive
true
exact text
metastatic BC after chemotherapy failure
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
143
context exact
l Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced
kind
biomarker
polarity
not_inferred
span
end
402
end exclusive
true
exact text
metastatic NSCLC after platinum therapy fai
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
359
context exact
e; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with predn
kind
biomarker
polarity
not_inferred
span
end
495
end exclusive
true
exact text
metastatic untreated NSCLC ( 1
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
465
context exact
ration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and
kind
biomarker
polarity
not_inferred
span
end
607
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
564
context exact
hibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adju
kind
stage_or_setting
polarity
not_inferred
span
end
174
end exclusive
true
exact text
locally advanced or metastatic BC after chemotherap
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
123
context exact
erapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC): single agen
kind
stage_or_setting
polarity
not_inferred
span
end
273
end exclusive
true
exact text
adjuvant treatment of operable node-positiv
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
230
context exact
1.1 ) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, local
kind
stage_or_setting
polarity
not_inferred
span
end
390
end exclusive
true
exact text
locally advanced or metastatic NSCLC after platinum
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
339
context exact
SCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Cas
kind
stage_or_setting
polarity
not_inferred
span
end
443
end exclusive
true
exact text
unresectable
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
431
context exact
tinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with predn
kind
stage_or_setting
polarity
not_inferred
span
end
495
end exclusive
true
exact text
locally advanced or metastatic untreated NSCLC ( 1
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
445
context exact
ration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and f
kind
stage_or_setting
polarity
not_inferred
span
end
609
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
564
context exact
cinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous C
kind
stage_or_setting
polarity
not_inferred
span
end
707
end exclusive
true
exact text
advanced GC
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
696
context exact
with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
896
end exclusive
true
exact text
locally advanced SCCHN ( 1
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
870

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
320
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
286

source span

end: 900
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%220bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61%22

spl effective date

2024-08-01

spl set id

2c806400-5fdc-4398-8475-37f700b3191f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

NDA203551

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1268
end exclusive: true
exact text: ced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 701

current approval status

not_reconciled

duplicate text group

dup-3a9eaa748829d308eed4

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-ae36ae49e8ce79226d06

label id

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

positive predicate support span

end: 951
end exclusive: true
exact text: is indicated
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 939

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1050
end exclusive
true
exact text
metastatic breast cancer after failure of p
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1007
context exact
l Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1038
end exclusive
true
exact text
locally advanced or metastatic breast cancer after
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
987

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
320
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
286

source span

end: 1068
end exclusive: true
exact text: 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 901

source url

https://api.fda.gov/drug/label.json?search=id%3A%220bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61%22

spl effective date

2024-08-01

spl set id

2c806400-5fdc-4398-8475-37f700b3191f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · positive indication candidate

application numbers

NDA203551

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1436
end exclusive: true
exact text: locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior p
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 869

current approval status

not_reconciled

duplicate text group

dup-c5d088bfdae04a75c4b2

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-7cc796a67d59c9ccace4

label id

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

positive predicate support span

end: 1154
end exclusive: true
exact text: is indicated
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1142

qualifier mentions

context exact
with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1206
end exclusive
true
exact text
adjuvant treatment of patients with operabl
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1163
context exact
Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
regimen
polarity
not_inferred
span
end
1235
end exclusive
true
exact text
in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1089

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
320
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
286

source span

end: 1236
end exclusive: true
exact text: Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1069

source url

https://api.fda.gov/drug/label.json?search=id%3A%220bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61%22

spl effective date

2024-08-01

spl set id

2c806400-5fdc-4398-8475-37f700b3191f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 4 · positive indication candidate

application numbers

NDA203551

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1663
end exclusive: true
exact text: failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously recei
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1037

current approval status

not_reconciled

duplicate text group

dup-886e3acfad5fd2d06f0e

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-dee247477409e0beafe5

label id

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

positive predicate support span

end: 1318
end exclusive: true
exact text: is indicated
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1306

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1417
end exclusive
true
exact text
metastatic non-small cell lung cancer after
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1374
context exact
ingle agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1405
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1354
context exact
1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
regimen
polarity
not_inferred
span
end
1462
end exclusive
true
exact text
as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1288

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
320
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
286

source span

end: 1463
end exclusive: true
exact text: 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1237

source url

https://api.fda.gov/drug/label.json?search=id%3A%220bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61%22

spl effective date

2024-08-01

spl set id

2c806400-5fdc-4398-8475-37f700b3191f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · positive indication candidate

application numbers

NDA203551

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1899
end exclusive: true
exact text: cer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Doce
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1264

current approval status

not_reconciled

duplicate text group

dup-f0b33c94e25c2253dcd8

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-98e72d1e113adbfc0cfa

label id

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

positive predicate support span

end: 1526
end exclusive: true
exact text: is indicated
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1514

qualifier mentions

context exact
reatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
biomarker
polarity
not_inferred
span
end
1639
end exclusive
true
exact text
metastatic non-small cell lung cancer who h
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1596
context exact
h cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer
kind
stage_or_setting
polarity
not_inferred
span
end
1574
end exclusive
true
exact text
unresectable
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1562
context exact
indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for thi
kind
stage_or_setting
polarity
not_inferred
span
end
1627
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1576
context exact
Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
regimen
polarity
not_inferred
span
end
1663
end exclusive
true
exact text
in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously recei
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1484

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
320
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
286

source span

end: 1699
end exclusive: true
exact text: Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1464

source url

https://api.fda.gov/drug/label.json?search=id%3A%220bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61%22

spl effective date

2024-08-01

spl set id

2c806400-5fdc-4398-8475-37f700b3191f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · positive indication candidate

application numbers

NDA203551

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2067
end exclusive: true
exact text: ith cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1500

current approval status

not_reconciled

duplicate text group

dup-5f90241eebd397d44155

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-488468ff79ad823bcbb5

label id

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

positive predicate support span

end: 1783
end exclusive: true
exact text: is indicated
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1771

qualifier mentions

context exact
prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
biomarker
polarity
not_inferred
span
end
1862
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1819
context exact
prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1864
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1819
context exact
1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
regimen
polarity
not_inferred
span
end
1866
end exclusive
true
exact text
in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1740

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
320
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
286

source span

end: 1867
end exclusive: true
exact text: 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1700

source url

https://api.fda.gov/drug/label.json?search=id%3A%220bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61%22

spl effective date

2024-08-01

spl set id

2c806400-5fdc-4398-8475-37f700b3191f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · positive indication candidate

application numbers

NDA203551

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2364
end exclusive: true
exact text: hemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the h
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1668

current approval status

not_reconciled

duplicate text group

dup-ba66021eb90188c98585

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-e709fc1b8d11abef770b

label id

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

positive predicate support span

end: 1974
end exclusive: true
exact text: is indicated
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1962

qualifier mentions

context exact
luorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction,
kind
stage_or_setting
polarity
not_inferred
span
end
2041
end exclusive
true
exact text
advanced gastric adenocarcinoma
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
2010
context exact
geal junction, who have not received prior chemotherapy for advanced disease.
kind
stage_or_setting
polarity
not_inferred
span
end
2163
end exclusive
true
exact text
advanced disease
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
2147
context exact
1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advance
kind
regimen
polarity
not_inferred
span
end
2094
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal ju
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
1915

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
320
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
286

source span

end: 2164
end exclusive: true
exact text: 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1868

source url

https://api.fda.gov/drug/label.json?search=id%3A%220bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61%22

spl effective date

2024-08-01

spl set id

2c806400-5fdc-4398-8475-37f700b3191f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 8 · positive indication candidate

application numbers

NDA203551

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2385
end exclusive: true
exact text: indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 1965

current approval status

not_reconciled

duplicate text group

dup-136b4642ab67d2b4a396

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-6a7151a618dcaede187b

label id

0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61

positive predicate support span

end: 2269
end exclusive: true
exact text: is indicated
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 2257

qualifier mentions

context exact
l is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
stage_or_setting
polarity
not_inferred
span
end
2366
end exclusive
true
exact text
locally advanced squamous cell carcinoma of the hea
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
2315
context exact
1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
regimen
polarity
not_inferred
span
end
2384
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
2210

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-Small Cell Lung Cancer
definition span
end
320
end exclusive
true
exact text
Non-Small Cell Lung Cancer (NSCLC)
label id
0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start
286

source span

end: 2385
end exclusive: true
exact text: 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: 0bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c1aba283456855c2d253c10ae1de73d32153588e564c79b64ac4bf50ea5e598f
start: 2165

source url

https://api.fda.gov/drug/label.json?search=id%3A%220bc8d3b7-f15e-4dbf-b51f-8baaa93b0e61%22

spl effective date

2024-08-01

spl set id

2c806400-5fdc-4398-8475-37f700b3191f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice